Our objective was to characterize the role of grafted cells in determining telomere length (TL) after hematopoietic SCT (HSCT). A total of 20 patients undergoing autografts had PBSC collected after two sequential mobilization courses: TL in the first collection was significantly longer than in the second. For their autografts, 10 patients used PBSC from the first collection and 10 from the second. TL was also investigated before and after HSCT and on the graft in 10 allogeneic HSCT. After autografting, patients receiving PBSC from the first collection had BM TL reflecting that of grafted cells (median bp: 7730 on PBSC vs 7610 on post-HSCT BM, P ¼ NS) and significantly longer than TL of the second collection; analogously, patients autografted with PBSC from the second collection had BM TL reflecting that of grafted cells (7360 on PBSC vs 7120 on post-HSCT BM, P ¼ NS) and significantly shorter compared with the first collection. In the allograft setting, eight patients had their pre-transplant TL significantly shorter than donor PBSC (5960 vs 7110; P ¼ 0.0005); following HSCT, BM TL (median 7380 bp) was identical to that of the graft (P ¼ NS). We conclude that grafted cells have a major role in determining TL after HSCT.
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Introduction
Telomeres are complexes of non-coding DNA sequences combined with proteins that cap chromosomal ends and sustain chromosomal stability. [1] [2] [3] [4] [5] At each cellular division, telomeric DNA is not fully replicated because DNA polymerases are unable to replicate the ends of linear DNA strands. [6] [7] Consequently, each somatic cell division is associated with a loss of telomeric DNA. Thus, telomere length represents a biomarker of somatic cell age and mitotic potential both in vitro and in vivo. [8] [9] [10] [11] Indeed, in healthy subjects, telomeres shorten with age in all replicating somatic cells, including leukocytes, at a rate of approximately 20-50 bp per year. [10] [11] [12] [13] [14] In the human hematopoietic system, increased telomere shortening has been documented in leukocytes from patients exposed to conventional or myeloablative chemotherapy with autograft. [15] [16] Also, regeneration after allogeneic hematopoietic SCT (HSCT) has been associated with accelerated telomeric shortening. [16] [17] [18] However, long-term assessment of telomere length (TL) after HSCT has shown inconsistent results regarding the degree and persistence of telomere shortening. [19] [20] [21] [22] In the autologous setting, inconsistency may depend on the variable extent of chemotherapy delivered before an autograft. [22] [23] [24] [25] In the allogeneic setting, the age of the donor might influence post-graft cell aging. 16 In both instances, the TL of the graft might have a key role in determining the ultimate TL shortening after transplantation.
In this study, we took advantage of a unique high-dose (hd) program, characterized by two sequential PBSC harvests. In a previous study, a marked difference in TL between first and second PBSC harvests has been documented. 24 Thus, TL has now been monitored in patients autografted with either the first or the second PBSC collection. Moreover, TL has been verified in a group of patients undergoing allogeneic HSC transplant. In all instances, post-transplant TL reflected that of grafted cells, proving that grafted cells have a major role in determining telomere status after HSCT.
Patients and methods

Patients
Telomere length was compared in the graft and in BM cells from a series of adult patients who either received autologous or allogeneic HSCT for hematological malignancies.
All HSCT programs had been approved by the local ethical committee. All patients were over 18-years old and provided written informed consent before undergoing the transplant program. They were either treated at the University Hematology Division at San Giovanni Hospital in Torino, Italy or at the University Hematology Division at the Istituto Nazionale Tumori in Milano, Italy.
The autograft program
All patients that received autografts underwent identical chemotherapy programs characterized by sequential administration of two tightly spaced hd-chemotherapy courses, both followed by PBSC mobilization and harvesting to be implemented for the final myeloablative treatment with autografting. , then Dexamethasone, Cytarabine and Cisplatin or Oxaliplatin); this was followed by the hd-sequential phase, i.e., hd-CY, 7 g/m 2 followed by a first PBSC collection, then hd-Cytarabine (hd-Ara-C, 2 g/m 2 ) given every 12 h for a total of 12 doses, followed by a second PBSC harvest. 24 Both hd-courses were supported by G-CSF to reduce the hematological toxicity and to improve CD34 þ cell mobilization. 26 In addition, small aliquots of CD34 þ cells (1-3 Â 10 6 /kg) collected after hd-CY were re-infused after hd-Ara-C. This allows to markedly reduce the hematopoietic toxicity of hd-Ara-C and favors large PBSC collections at hematological recovery in virtually all patients, as previously documented. 27 Rituximab was infused immediately before both PBSC collections for in vivo purging. 28, 29 The auto-SCT procedure included a combination of hd-Mitoxantrone (60 mg/m 2 ) started on day 5 and hd-Melphalan (180 mg/m 2 ) started on day 2. 30 The main clinical features of the patients receiving autologous HSCT are reported in Table 1 .
The allograft program
All patients who received allogeneic HSCT underwent a reduced-intensity conditioning approach and, in most cases, the donor was younger. In all 10 patients received a PBSC allograft from an HLA-identical sibling. Sex mismatch between donor and recipient was present in four cases. In order to verify potential changes in TL before and after transplantation, patients selected for the study had a markedly different TL from that of their matching donor. Chimerism was monitored at 1, 3, 6 and 12 months after HSCT.
All patients received various chemotherapy schedules to treat hematological neoplasia before undergoing the allogeneic transplant. Their main clinical features are reported in Table 1 . All patients received a reducedintensity conditioning regimen, seven of them with the Thiotepa-Fludarabine-CY combination, and two with the TBI 200 cGy scheme. [31] [32] One lymphoma patient entered the HDS program, but instead of an autograft, received a ) and rapidly engrafted, with full chimerism achieved at 30-180 days. A 6-month immunosuppression treatment with CsA plus MTX was included in the allograft program.
TL analysis
Telomere length was assessed in mononuclear cells from leukapheresis and BM samples obtained after transplantation. In order to evaluate TL at complete and stable engraftment, post-transplant samples were taken after a minimum of 8 months (median 14, range 8-18 months) after the transplantation procedure. In all instances, only patients in continuous CR after transplantation were considered. In addition, the absence of BM infiltration by lymphoma cells was documented with histological and immunophenotypic analysis in all the analyzed samples. Samples of BM were taken during routine restaging procedures. Mononuclear cells were then separated on Ficoll gradients. We previously showed similar results when TL was measured in mononuclear cells and in separated CD34 þ cells. 24 TL evaluation was carried out by Southern blot analysis as described elsewhere. 24 Briefly, 2 mg of DNA were digested by mixing HinfI (20 U) and RsaI (20 U) (Roche Diagnostic, Mannheim, Germany) and incubating at 37 1C for 2 h. Resulting DNA fragments were then separated on a 0.8% agarose gel by electrophoresis in 1 Â TAE running buffer. Separated DNA was subsequently transferred to a positively charged nylon membrane. After an overnight transfer, the membrane was exposed to UV light to fix DNA fragments. The TeloTAGGG TL assay kit (Roche Diagnostic, Mannheim, Germany) was used for the hybridization phase. Membranes were submerged in a pre-hybridization solution and then incubated in the hybridization solution (2 ml of the digoxigenin-labeled telomere-specific probe added to the prehybridization solution) for 3 h at 62 1C. Then, membranes with DNA fragments linked to telomere probes were incubated with a digoxigenin-specific Ab covalently coupled to alkaline phosphatase. Finally, CDP-Star was dropped onto the membrane to stimulate alkaline phosphatase to emit light. This emission was captured on an X-ray film (Lumi-Film Chemiluminescent Detection Film, Roche Diagnostic, Mannheim, Germany) and scanned for analysis. Each sample was analyzed twice and for each telomere smear, median TRF length was calculated using the software Quantity One by Biorad (Hemel Hempstead, UK). 33 
Statistical methods
The Student's t-test was used to compare telomere lengths evaluated at different time points. Differences were considered significant for Po0.05. Statistical analysis was carried out with the statistical software package GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA).
Results
PBSC mobilization and re-infusion for autografts
All patients undergoing the HDS program with autograft displayed adequate progenitor cell mobilization, both at the first (hd-CY) and second (hd-Ara-C) mobilization courses. Large amounts of CD34 þ cells were collected, and a median of 2 leukapheresis procedures were carried out after each hd-chemotherapy course. ) was harvested after hd-CY and hd-Ara-C, respectively. The amounts of CD34 þ cells harvested in the two mobilization rounds were not statistically different (data not shown).
All patients received adequate quantities of CD34 þ cells for autograft (median 7.50 Â 10 6 CD34 þ /kg, range 3.27 Â 10 Despite similar CD34 þ cell quantities, TL was markedly reduced in the second PBSC harvest (post-hd-Ara-C) compared with the first (post-hd-CY leukapheresis), which is consistent with our previous report. 24 The median TL on harvested cells was 8050 bp (range 5210-11 020 bp) and 7070 (range 4800-8910 bp), after hd-CY and hd-Ara-C, respectively (Po0.0001). Table 2 Blood cell counts at the time telomere length was assessed after transplantation Autografted patients with PBSC Allografted patients (n ¼ 10)
Hb median (range) 13. In all settings, patients displayed a post-HSCT BM TL correspondent to that of the grafted cells. As shown in Figure 2a , the median post-autograft TL in patients who received autografts with PBSC collected early was similar to that of the grafted PBSC, and significantly longer than that of the PBSC collected after the second hd-course. Similarly, patients who received PBSC collected late (post hd-Ara-C) showed a post-autograft TL analogous to that of grafted cells, and thus significantly shorter compared with PBSC of the first harvest, as shown in Figure 2b .
Smears of TRF length measurement in two representative patients, autografted with post hd-Ara-C (case a) and post-CY (case b) PBSC are shown in Figure 3 .
Long-term assessment of TL after allografts All 10 patients who received allografts displayed full hematogical reconstitution, with normal cell blood count at the long-term follow-up after the allograft procedure, as detailed in Table 2 .
Telomere length was assessed in recipients on preallograft BM samples and in PBSC from the compatible donors. TL was then assessed on BM samples at a median of 14 months after the allogeneic transplant. In all eight patients receiving donor PBSC with TL longer than that of the recipient (median TL: 71 10 bp, range 6840-9100), posttransplant TL was similar to that of the donor cells, and consistently longer than the TL of the recipient preallograft cells (see Table 3 , case #1-8). For these eight allografted patients, TL in BM cells after the allograft was significantly increased (median TL: 7380 bp, range 6480-7940) compared with pre-transplant values (5960 bp (4440-6830) Po0.0007). In two more cases, donor PBSC had a TL shorter than that of the recipient (Table 3 , case #9-10). Again, post-transplant TL was similar to that of the donor cells and, thus, shorter than the TL of the recipient preallograft cells. Changes of TL after allograft were not influenced by sex combination of donor and recipient. Smears of TRF length measurement in a representative patient receiving PBSC allogeneic transplant (case # 7) are shown in Figure 3 .
Discussion
The present study was aimed to analyze TL of BM cells after HSCT and to investigate whether the TL of grafted cells influences the post-graft TL. For this purpose, TL was evaluated in the long-term follow-up after HSCT in 20 subjects treated with hd-chemotherapy and PBSC autografts and in 10 subjects given reduced-intensity allogeneic transplants. A rigorous comparative analysis of TL was carried out before and after transplantation, including an accurate characterization of the grafted cells. In all instances, the post-transplant TL was analogous to that of the grafted cells. Thus, in both autologous and allogeneic HSCT, the use of cells with long TL for grafting is suggested to minimize the risk of post-HSCT telomere erosion and presumably of cell aging of the reconstituted hematopoietic system. Moreover, results indicate that cell proliferation stress during post-transplant engraftment has a minor impact on post-HSCT telomere status. This study took advantage of the accessibility of BM samples from patients enrolled in our ongoing hdchemotherapy program with PBSC autograft. The twofold PBSC harvest after two consecutive courses of hd chemotherapy is a unique feature of the scheme. A previous report demonstrated that telomere loss was greater in the second compared with the first PBSC harvest. 24 For this study, the ongoing protocol offered the opportunity to analyze two sets of homogeneously treated patients. The only distinct feature of the two patient populations was the TL of the graft, i.e. a longer TL for those that received the first, post-CY, harvest compared with a shorter TL for those that received the second, post-Ara-C, harvest. Two main factors may explain the markedly reduced TL in PBSC of the second harvest, i.e. the repeated exposure to cytotoxic drugs and the re-infusion after hd-Ara-C of some aliquots of CD34 þ cells previously collected following hd-CY. Indeed, CD34 þ cells undergo unusual proliferation stress during the sequence hd-CY through hd-Ara-C. This justifies the rapid telomere loss in the very short interval elapsed between the two hd-courses.
Thus, in the hd-program with autograft there were two main groups of patients, differing for the length of telomere of their autografted PBSC. This allowed a straightforward analysis of the influence of the graft on telomere changes after hd-chemotherapy with an autograft. A series of patients undergoing allogeneic transplants was also evaluated, with the aim of carrying out a comparable evaluation of TL changes, but using donor cells not previously exposed to cytotoxic drugs. We only selected patients who had pre-transplant TLs clearly different from that of their donors. In all instances, TL was assayed at full and stable hematopoietic reconstitution. This allowed assessment of TL modifications that were firmly established following both autologous and allogeneic HSCT, and omitted transient changes that might occur in the early phase after transplantation. 20, 22, 34 The degree of telomere loss after HSCT and the underlying mechanisms have been investigated in several studies with controversial results. [16] [17] [18] [19] [20] [21] [22] The stress of proliferation during BM reconstitution has been proposed as the main cause of post-graft TL shortening. 35 However, at least in the autograft setting, previous exposure of grafted cells to chemotherapy may represent an alternative and predominant path leading to telomere loss. 16, 22 Accelerated telomere shortening appears to be limited to the first year after allogeneic HSCT, suggesting a minor and transient role of engraftment stress, also in the allogeneic HSCT. [20] [21] [36] [37] However, many factors can influence post-transplant hematopoietic senescence after allogeneic HSCT, such as the occurrence of chronic GVHD, the donor-recipient grade of HLA compatibility, donor sex and the protocol of conditioning chemotherapy. In particular, it has been recently reported that both chronic GVHD and female donor sex may influence cellular senescence of WBCs in very long-term survivors after allogeneic HSCT. 38 
Table 3
Telomere length in 10 allografted patients before and after transplant and in their matching donor Abbreviation: MM ¼ multiple myeloma; NHL ¼ non-Hodgkin's lymphoma. a Telomere length (TL) was assessed in all allografted patients on BM cells taken before transplant and at a median of 14 months after transplantation b TL was assessed on PBSC from leukapheresis products from the 10 matching donors; TL was longer in donor PBSC than in pre-transplant BM recipients for case nos. 1-8, whereas it was shorter in cases 9 and 10.
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In our analysis, TL was assessed early after allograft, at approximately 14 months after HSCT. Results of the study are consistent with the notion that the degree of cell aging of the graft is the main factor influencing post-transplant TL. In particular, patients with short TL displayed reconstituted hematopoietic cells with a longer TL than previously, when the grafts used had longer telomeres. It should be mentioned that in our study, patients undergoing allogeneic HSCT received a reduced-intensity conditioning regimen. However, no marked differences have been observed in telomere dynamics in conventional and reduced-intensity allogeneic HSCT. 39 In our studies, BM reconstitution had little or no influence on post-transplant TL, neither in the allogeneic nor the autologous HSCT subgroups. Indeed, our results suggest that HSCT should be preferentially carried out with cells that have a long TL, in order to overcome the potential telomere loss that occurs during early post-transplant engraftment. It is interesting to note that these findings are in concordance with a recent analysis in 6978 transplant recipients documenting that advanced donor age was significantly associated with reduced chances of favorable outcome. 40 Further studies on large series of patients, followed at very long term, are required to investigate all other factors, besides the type of graft, that may influence cell senescence following allogeneic HSCT.
The issue of TL loss is of particular concern in the autograft setting. In fact, several observations have indicated a potential association between short telomeres and the development of secondary tumors, in particular, secondary myelodysplastic syndrome/acute leukemia. [41] [42] [43] [44] [45] In fact, secondary myelodysplastic syndrome/acute leukemia at present is considered to be the most frightening complication of the autograft approach. On the other hand, intensive chemotherapy is the central feature of autograftbased programs. Recently, intensive and highly effective schedules have been developed, exploiting an extensive and cyclic use of the autologous PBSC. [46] [47] [48] However, repetitive exposure to hd-cytotoxic drugs with stem-cell turnover has been shown to induce progressive and marked telomere loss in hematopoietic cells. [24] [25] This condition might lead to an increased risk of secondary myelodysplastic syndrome/ acute leukemia. Results reported suggest that autologous PBSCs, which have not been extensively exposed to chemotherapy, should be obtained early in the intensive program and maintained as a back-up source of PBSC for the autograft. In protocols that include an intensified treatment, these PBSC may be re-infused during the last autograft procedure, allowing the reconstitution of hematopoietic cells that have TLs analogous to those that were displayed in BM cells before the administration of the intensive cytotoxic courses.
Results of the present study stress the adverse effect of previous exposure to chemotherapy on the TL of harvested cells. Indeed, it is well established that telomeres in individuals treated with chemotherapy are shorter than age-matched controls that have never been exposed to these drugs. However, it remains to be defined whether telomeres may be modulated, directly or indirectly, by anticancer drugs. 49 For instance, potential risk factors, including age, gender, type of underlying cancer and lifestyle, should be further investigated for an association with chemotherapyinduced telomere loss. 50 Moreover, it remains to be clarified whether the premature telomere shortening that occurs after chemotherapy is merely the result of the replicative stress of hematopoietic cells or, more likely, a side effect of a complex process involving various genes implicated in DNA repair mechanisms. [51] [52] [53] [54] Patients with dramatic changes in telomere size in response to cytotoxic drug exposure may offer an opportunity to investigate potential relationships between the activation of genes for DNA repair and progression towards cell aging.
Whether re-infused cells or resident cells that survive hdchemotherapy have a predominant role in BM repopulation is still a matter of debate, at least in the autologous setting. Our study indicated that after PBSC transplantation, BM is mainly, if not entirely, generated by re-infused cells. In fact, a telomere restriction fragment can be considered a marker of a specific cell population; the similarity in TLs found in re-infused cells and posttransplant cells strongly supports the notion that re-infused cells have a predominant role in post-transplant BM recovery. Taken together, these observations suggest grafting procedures should preferentially include younger donor cells whenever possible. This would allow the maintenance of adequate telomere lengths in post-transplant BM cells, and ultimately the rejuvenation of the hematopoietic system in patients that experience telomere shortening due to heavy cytotoxic pre-treatments. In order to validate this suggestion, we are currently investigating TL in a large series of adult patients that have been transplanted with cord blood cells, an indisputably 'young' graft with a high proliferative potential and long TL. 5, 55 Results will clarify whether transplantation may also be viewed as a tool for rejuvenating the hematopoietic system.
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